Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults with SAnD
It is very uncertain whether comparison 4: antipsychotics changes global Impressions scale change item (CGI‐I or similar): no. of… compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with SAnD
It is very uncertain whether comparison 4: antipsychotics changes dropouts due to adverse events (acute phase) compared with placebo (very low certainty).
1 finding from 1 review
Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score · adults with SAnD
1 finding from 1 review
no estimate extracted
1 study · 9 participants
Very low
Specific behaviour ‐ agitation
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Response for agitation ‐ as defined by authors of RCTs ‐ 1303 persons in 4 RCTs of 3 to 12 weeks
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Psychosis ‐ presented in units of NPI‐NH P (higher is worse)d ‐ 3364 persons in 12 RCTs of 3 to 12 weeks
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Response for psychosis ‐ as defined by authors of RCTs ‐ 1958 persons in 7 RCTs of 3 to 12 weeks
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Adverse effects/events ‐ extrapyramidal symptoms ‐ medium term Number of instances of extrapyramidal symptoms
1 finding from 1 review
no estimate extracted
Studies not reported
High
Somnolence
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Death ‐ 5032 persons in 17 RCTs of 3 to 12 weeks ___________________________________________
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Psychosis ‐ presented in units of NPI‐NH P (higher is worse)d ‐ 3364 persons in 12 RCTs of 3 to 12 weeks
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Response for psychosis ‐ as defined by authors of RCTs ‐ 1958 persons in 7 RCTs of 3 to 12 weeks
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Adverse effects/events ‐ extrapyramidal symptoms ‐ medium term Number of instances of extrapyramidal symptoms
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Somnolence
1 finding from 1 review
no estimate extracted
Studies not reported
High
Death ‐ 5032 persons in 17 RCTs of 3 to 12 weeks ___________________________________________
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Specific behaviour ‐ agitation
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Response for agitation ‐ as defined by authors of RCTs ‐ 1303 persons in 4 RCTs of 3 to 12 weeks
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Adverse effects: 1. Sedation · psychosis‐induced aggression or agitation
Benzodiazepines + antipsychotics showed no clear difference in tranquillisation or asleep: sedation ‐ medium term‐ + haloperidol ‐… compared with same enzodiazepines (low certainty).
1 finding from 1 review
Global state: no improvement ‐ + haloperidol ‐ medium term As defined in each study · psychosis‐induced aggression or agitation
Benzodiazepines + antipsychotics showed no clear difference in global state: no improvement ‐ + haloperidol ‐ medium term As… compared with same enzodiazepines (low certainty).
1 finding from 1 review
Global state: no improvement ‐ medium termAs defined in each study · psychosis‐induced aggression or agitation
Benzodiazepines + antipsychotics showed no clear difference in global state: no improvement ‐ lorazepam + risperidone vs lorazepam… compared with same enzodiazepines (low certainty).
1 finding from 1 review